Finance

Lists
LAB:NASDAQ
Standard Biotools Inc
$0.79
+0.84%
(+0.0066) 1D
$0.79
0.00% (0.00)
After hours
Closed: Aug 12, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LAB...
Open
$0.77
High
$0.80
Low
$0.77
Mkt. cap
309.16M
Avg. vol.
2.34M
Volume
0.00
52-wk high
$1.72
52-wk low
$0.70
Beta
1.40
Shares outstanding
392.58M
No. of employees
387
Open
$0.77
High
$0.80
Low
$0.77
Mkt. cap
309.16M
Avg. vol.
2.34M
Volume
0.00
52-wk high
$1.72
52-wk low
$0.70
Beta
1.40
Shares outstanding
392.58M
No. of employees
387
News stories
From web sources and news partners
Profile
Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits, and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications. Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations. Wikipedia
About Standard Biotools Inc
CEO-
Employees387
Founded1999
HeadquartersBoston, Massachusetts, United States
SectorHealth care
Analyst
Recommendation
Action
Price target
Projected
Date
Kyle Boucher
TD Cowen
Hold
Maintained
$1.35
+70%
05/05/2026
Paul Knight
KeyBanc
Hold
Maintained
-
-
02/25/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.07 / -$0.01
-600.00%miss
Revenue / Est. (USD)
20.10M / 20.80M
-3.35%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
19.55M
23.80M
21.15M
20.10M
Cost of goods sold
10.07M
12.41M
11.79M
9.57M
Cost of revenue
10.07M
12.41M
11.79M
9.57M
Research and development expenses
6.36M
7.97M
162.00K
1.98M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.60M
25.34M
18.61M
16.39M
Operating expense
32.95M
33.31M
18.77M
18.36M
Total operating expenses
43.02M
45.72M
30.56M
27.93M
Operating income
-23.47M
-21.92M
-9.42M
-7.83M
Other non operating income
-2.09M
4.96M
-2.14M
-15.40M
EBT including unusual items
-32.90M
-22.03M
-14.62M
-21.44M
EBT excluding unusual items
-23.43M
-15.31M
-8.04M
-18.62M
Income tax expense
-1.22M
-35.93M
11.00K
90.00K
Effective tax rate
3.70%
163.10%
-0.08%
-0.42%
Other operating expenses
-
-
-
-
Net income
-34.69M
19.28M
127.07M
-26.76M
Net profit margin
-177.41%
81.04%
600.91%
-133.10%
Earnings per share
-0.04
0.07
-0.02
-
Interest and investment income
2.14M
1.66M
3.51M
4.61M
Interest expense
-10.00K
-5.00K
-
-
Net interest expenses
2.13M
1.66M
3.51M
4.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.87M
-16.64M
-8.01M
-6.56M
Gain or loss from assets sale
-
-
-
-172.29M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps